Craig I Coleman (C I Coleman, Craig Coleman)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 39

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Systematic Review

Chronic Kidney Disease

Top Venues

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Current medical research and opinion

Pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander T Cohen, Christopher Wallenhorst, Marcella Rivera, Cihan Ay, Bernhard Schaefer, Khaled Abdelgawwad, George Psaroudakis, Gunnar Brobert, Anders Ekbom, Agnes Y Y Lee, Alok A Khorana, Cecilia Becattini, Marc Carrier, Craig I Coleman, Carlos Martinez
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study. Thrombosis and haemostasis (2024)
C Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V Hernández, William L Baker, Paul P Dobesh, Heleen van Haalen, Kirsty M Rhodes, Craig I Coleman
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis. Pharmacotherapy (2024)
C Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V Hernández, William L Baker, Paul P Dobesh, Heleen van Haalen, Kirsty M Rhodes, Craig I Coleman
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis. Pharmacotherapy 44 (5) (2024)
Alexander Cohen, Christopher Wallenhorst, Marcela Rivera, Cihan Ay, Bernhard Schaefer, Khaled Abdelgawwad, George Psaroudakis, Gunnar Brobert, Anders Ekbom, Agnes Y Y Lee, Alok A Khorana, Cecilia Becattini, Marc Carrier, Craig I Coleman, Carlos Martinez
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low Molecular Weight Heparin - The OSCAR-UK Study. Thrombosis and haemostasis (2024)
William L Baker, Mukul Sharma, Alexander Cohen, Mario Ouwens, Mary J Christoph, Bruce Koch, Timothy E Moore, Garrett Frady, Craig I Coleman
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model. PloS one 19 (5) (2024)
William L Baker, Mukul Sharma, Alexander Cohen, Mario Ouwens, Mary J Christoph, Bruce Koch, Timothy E Moore, Garrett Frady, Craig I Coleman
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model. PloS one 19 (5) (2024)
William L Baker, Mukul Sharma, Alexander Cohen, Mario Ouwens, Mary J Christoph, Bruce Koch, Timothy E Moore, Garrett Frady, Craig I Coleman
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model. PloS one 19 (5) (2024)
C Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V Hernández, William L Baker, Paul P Dobesh, Heleen van Haalen, Kirsty M Rhodes, Craig I Coleman
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis. Pharmacotherapy 44 (5) (2024)
Kimberly Snow Caroti, Cecilia Becattini, Marc Carrier, Alexander T Cohen, Anders Ekbom, Alok A Khorana, Agnes Y Y Lee, Christopher Brescia, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Bernhard Schaefer, Gunnar Brobert, Craig I Coleman
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding. TH open : companion journal to thrombosis and haemostasis 7 (3) (2023)
William L Baker, Matthew S Roberts, Youssef Bessada, Kimberly S Caroti, Veronica Ashton, Brahim K Bookhart, Craig I Coleman
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies. Current medical research and opinion (2023)
Kimberly Snow Caroti, Alok A Khorana, Cecilia Becattini, Agnes Y Y Lee, Anders Ekbom, Marc Carrier, Alexander T Cohen, Christopher Brescia, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Bernhard Schaefer, Gunnar Brobert, Craig I Coleman
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 29 (2023)
Nitesh Sood, Veronica Ashton, Youssef Bessada, Katelyn Galli, Brahim K Bookhart, Craig I Coleman
Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea. TH open : companion journal to thrombosis and haemostasis 7 (1) (2023)
Tatsiana Vaitsiakhovich, Craig I Coleman, Frank Kleinjung, Burcu Vardar, Bernhard Schaefer
Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study. Current medical research and opinion 38 (6) (2022)
Craig I Coleman, Olivia S Costa, Christopher W Brescia, Burcu Vardar, Khaled Abdelgawwad, Lucas Hofmeister, Nitesh Sood
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Craig I Coleman, Akshay A Kharat, Brahim Bookhart, William L Baker
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. Current medical research and opinion (2021)
Craig I Coleman, Thomas J Bunz, Veronica Ashton
Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills. Current medical research and opinion (2021)
Olivia S Costa, Bridget O'Donnell, Burcu Vardar, Khaled Abdelgawwad, Christopher W Brescia, Nitesh Sood, Craig I Coleman
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. Current medical research and opinion 37 (9) (2021)
Craig I Coleman, Olivia S Costa
Welcome to the cardiovascular outcomes trials issue. Future cardiology 17 (3) (2021)
Olivia S Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J Bunz, Craig I Coleman
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. Journal of thrombosis and thrombolysis 51 (2) (2021)
Olivia S Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J Bunz, Craig I Coleman
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 26 (2021)
Tabassum Salam, Amy Duhig, Aarti A Patel, Ann Cameron, Jennifer Voelker, Brahim Bookhart, Craig I Coleman
Physicians' perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey. PloS one 15 (1) (2020)
Craig I Coleman, Gregory Piazza, Veronica Ashton, Thomas J Bunz, Alex C Spyropoulos
Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. TH open : companion journal to thrombosis and haemostasis 4 (4) (2020)
Craig I Coleman, Reinhold Kreutz, Nitesh Sood, Thomas J Bunz, Anna-Katharina Meinecke, Daniel Eriksson, William L Baker
Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 25 (2020)
Craig I Coleman, Paul P Dobesh, Sherry Danese, Julie Ulloa, Belinda Lovelace
Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future cardiology 17 (1) (2020)
Olivia S Costa, Jan Beyer-Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J Bunz, Craig I Coleman
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Current medical research and opinion 36 (7) (2020)
Benjamin Miao, Mark J Alberts, Thomas J Bunz, Craig I Coleman
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. Journal of thrombosis and thrombolysis 48 (3) (2020)
Benjamin Miao, Nitesh Sood, Thomas J Bunz, Craig I Coleman
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. European journal of haematology 104 (4) (2020)
Craig I Coleman, Tabassum Salam, Amy Duhig, Aarti A Patel, Ann Cameron, Jennifer Voelker, Brahim Bookhart
Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers. Journal of market access & health policy 8 (1) (2020)
Craig I Coleman, E R Weeda, A Kharat, B Bookhart, W L Baker
Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. Diabetic medicine : a journal of the British Diabetic Association 37 (1) (2019)
Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, Jan Beyer-Westendorf
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. Journal of thrombosis and thrombolysis 46 (3) (2019)
Brandon K Martinez, William L Baker, Nitesh A Sood, Thomas J Bunz, Anna-Katharina Meinecke, Daniel Eriksson, Craig I Coleman
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy 39 (2) (2019)
William L Baker, Jan Beyer-Westendorf, Thomas J Bunz, Daniel Eriksson, Anna-Katharina Meinecke, Nitesh A Sood, Craig I Coleman
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes, obesity & metabolism 21 (9) (2019)
Benjamin Miao, Bhavana Chalupadi, Brendan Clark, Alexis Descoteaux, Daniel Huang, Sabrina Ilham, Brian Ly, Alex C Spyropoulos, Craig I Coleman
Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 25 (2019)
Craig I Coleman, Tatsiana Vaitsiakhovich, Elaine Nguyen, Erin R Weeda, Nitesh A Sood, Thomas J Bunz, Bernhard Schaefer, Anna-Katharina Meinecke, Daniel Eriksson
Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clinical cardiology 41 (1) (2018)
Diana M Sobieraj, William L Baker, Eni Smith, Katarzyna Sasiela, Stephanie E Trexler, Oliver Kim, Craig I Coleman
Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 24 (9_suppl) (2018)
Brandon K Martinez, Jit Sheth, Nishi Patel, William L Baker, Craig I Coleman
Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. Pharmacotherapy 38 (6) (2018)
Christine G Kohn, Thomas J Bunz, Jan Beyer-Westendorf, Craig I Coleman
Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. European journal of haematology 102 (2) (2018)
Craig I Coleman, T J Bunz, D Eriksson, A-K Meinecke, N A Sood
Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabetic medicine : a journal of the British Diabetic Association 35 (8) (2018)
Craig I Coleman, Jan Beyer-Westendorf, Thomas J Bunz, Charles E Mahan, Alex C Spyropoulos
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 24 (4) (2018)